Development and Evaluation of Nanoemulsion of Primaquine for Prevention of Relapsing Malaria
| Autor: | Gurdeep Singh, Mohsina Khan, M.K. Gupta, Gulfisha Shaikh |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Drug
Primaquine biology business.industry media_common.quotation_subject Plasmodium vivax Pharmacology Plasmodium ovale biology.organism_classification medicine.disease Systemic circulation parasitic diseases medicine Malaria relapse General Earth and Planetary Sciences business Malaria General Environmental Science media_common medicine.drug |
| Zdroj: | Current Research in Pharmaceutical Sciences. 9:73-76 |
| ISSN: | 2250-2688 |
| Popis: | Malaria relapsing refers to the reactivation of the infection via Relapse, when symptoms reappear after the parasites have been eliminated from blood but persist as dormant hypnozoites in liver cells. Malaria relapse commonly occurs between 8–24 w and is commonly seen with P. Vivax and P. Ovale infections. Primaquine (PQ) is one of the most widely used antimalarial and is t he only available drug till date to combat relapsing form of malaria especially in case of Plasmodium Vivax and Plasmodium Ovale. Primaquine acts specifically on the pre-erythrocytic schizonts which are concentrated predominantly in the liver and causes relapse after multiplication but one of the major drawback of this drug is that it dissolves in less proportion in systemic circulation to show an active effect. So to reduce these effects, Primaquine incorporated into oral lipid nanoemulsion having particle size in the range of 10–200 nm. The absorbtion capacity of primaquine is significantly increased as nanoemulsion of Primaquine used. The drug is readily absorbed by the liver 45% more than before. So the results declared the successful absorbtion of primaquine by the liver in its nenoemulsion form as it will be used further in the treatment of malaria because it is less toxic. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|